Monday, 20 Jan 2020

You are here

Adalimumab FDA Approved for Hidradenitis Suppurativa

Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.

Approval is based on the results of two pivotal Phase 3 studies, PIONEER I and PIONEER II, that included 633 people with moderate to severe HS. Both studies showed that adalimumab significantly reduced the total number of abscesses and inflammatory nodules compared with patients given placebo. No new safety risks were identified in these trials.

The European Commission approved adalimumab for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic treatment.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I have treated a 58 y/o gentleman with Hydroadenitis associated arthritis using Inflixamab for approximately 8 years now. Excellent response of the arthritis and near complete resolution of skin lesions. Occasional mild skin lesion if infusion is delayed, which occurs due to pts. schedule, however, through the years there has been absolutely no need further surgical intervention regarding the Hydroadenitis. Prior to biological therapy, he frequently required surgical abscess resection, and just prior initiation of Inflixamab therapy, had a complete axillary dissection.

More Like This

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.